Nanospectra Biosciences, Inc. is commercializing a particle-based therapy for the selective and precise thermal destruction of solid tumors while minimizing damage to healthy adjacent tissue and preserving critical structures. This medical device, AuroLase™ Therapy, is broadly applicable to most solid tumors, and we have a pending application with FDA for an Investigation Device Exemption (IDE) to conduct the first clinical trial in patients with head and neck cancer. AuroLase Therapy utilizes